ライフサイエンスコーパス: eligibility

1 and 31 RCTs were systematically reviewed for eligibility.

2 n other domains, and domain and intervention eligibility.

3 der testing, such as ATM, for clinical trial eligibility.

4 LD as a comorbid indication when determining eligibility.

5 women with ALD may improve their transplant eligibility.

6 es, of which 109 were assessed for full-text eligibility.

7 455 patients were recruited and assessed for eligibility.

8 Oct 10, 2018, we screened 2027 children for eligibility.

9 nsurance coverage (vs uninsured), and income eligibility.

10 Tumor HA status was not required for eligibility.

11 gistered for the study and were assessed for eligibility.

12 reviewers assessed 46 full-text articles for eligibility.

13 ed 60-75 years were interviewed to establish eligibility.

14 porated for determining transplant candidate eligibility.

15 Sept 5, 2016, 976 patients were screened for eligibility.

16 ug 19, 2016, 1020 patients were screened for eligibility.

17 orneal densitometry module were screened for eligibility.

18 ients with type 2 diabetes were assessed for eligibility.

19 ext articles were retrieved and screened for eligibility.

20 63 references, of which 81 were screened for eligibility.

21 r use of these agents and for clinical trial eligibility.

22 participants were recruited and assessed for eligibility.

23 using these subjective criteria to determine eligibility.

24 ge, but used national EID guidelines for EID eligibility.

25 even clinical (n = 164 patients) studies met eligibility.

26 accurate and independent vetting of subject eligibility.

27 Sept 27, 2017, we assessed 288 patients for eligibility.

28 cratic hassles and difficulties establishing eligibility.

29 May 24, 2019, 198 patients were assessed for eligibility.

30 Of 559 full-text studies assessed for eligibility, 116 met eligibility criteria, which include

31 Of 124 patients screened for eligibility, 121 patients were randomly assigned, and 11

32 Of 782 patients assessed for eligibility, 130 (17%) patients were enrolled and 104 we

33 16, and March 28, 2019, of 2479 assessed for eligibility, 1315 people living with HIV and not on ART

34 Of 342 individuals screened for eligibility, 222 patients were randomly assigned to rece

35 Of 3553 women screened for eligibility, 2279 were enrolled (744 in SST clusters, 68

36 Of the 351 patients assessed for eligibility, 309 recruited between March 26, 2013, and M

37 ty, 3) a potential threat to tribal services eligibility, 4) broad informed consent language, and 5)

38 Of 457 patients screened for eligibility, 402 were randomly allocated-195 (49%) to th

39 rch 21, 2018, 205 patients were screened for eligibility, 48 were excluded and 157 patients (mean age

40 ine plus carboplatin, depending on cisplatin eligibility) administered intravenously for up to six cy

41 re more careful consideration for transplant eligibility after LVAD placement.

42 The Affordable Care Act expanded Medicaid eligibility allowing low-income individuals greater acce

43 May 15, 2018, 142 patients were assessed for eligibility and 102 were randomly assigned to group 1 (n

44 Jan 30, 2015, 149 patients were assessed for eligibility and 148 were then randomly assigned to recei

45 dred seventy-nine patients were assessed for eligibility and 176 randomized.

46 ver 17 months, 53 patients were assessed for eligibility and 36 (68%) were randomised (47% male; mean

47 55 patients were assessed for eligibility and 52 consented to enrolment.

48 pril 7, 2017, 807 patients were assessed for eligibility and 725 were randomly assigned to Amikacin I

49 Trial eligibility and data extraction were conducted according

50 general, and specifically regarding welfare eligibility and documentation requirements, were found t

51 nd Nov 1, 2017, we screened 729 patients for eligibility and enrolled 463 patients, who were initiate

52 istribution, (b) benefit allocation, and (c) eligibility and enrollment.

53 Studies were reviewed according to eligibility and exclusion criteria.

54 Two researchers independently assessed eligibility and extracted data.

55 asis of greater guideline-recommended statin eligibility and higher rates of statin therapy.

56 Patients were screened for eligibility and included if they were 18 years or older,

57 ter alternative to easily indicate treatment eligibility and might help scale-up treatment interventi

58 We then estimated eligibility and number of events that would occur during

59 rgan donors after brain death increased lung eligibility and procurement.Objectives: This prospective

60 searchers screened all records for potential eligibility and quality.

61 before randomisation to confirm participant eligibility and rate features of the intracerebral haemo

62 feasible procedures for determining same-day eligibility and readiness is now a priority.

63 eviewers independently assessed articles for eligibility and risk of bias, and conflicts were resolve

64 Two reviewers independently assessed eligibility and risk of bias, with conflicts resolved by

65 ysis, CXR-LC had higher net benefit than CMS eligibility and similar benefit to PLCO(M2012).

66 Treatment eligibility and the accuracy of its simplified criteria

67 gh risk for incident lung cancer, beyond CMS eligibility and using information commonly available in

68 al of 177 persons with ALS were screened for eligibility, and 137 were randomly assigned to receive s

69 ressive multiple sclerosis were screened for eligibility, and 140 were randomly assigned to either th

70 ublished full-text records were assessed for eligibility, and 77 studies were included (19 364 partic

71 Jan 31, 2019, 230 patients were assessed for eligibility, and as of the Jan 31, 2019 data cutoff date

72 therapies, in terms of determining treatment eligibility, as well as adjusting or adding supportive m

73 n of simple risk scores for liver transplant eligibility assessment leads to selection of patients at

74 Eligibility assessment was performed independently by tw

75 and 3.8% (88 related to 2289 with completed eligibility assessment).

76 to transition from the standard of care (ART eligibility at CD4 counts of <350 cells/mm3 until Septem

77 1173 infants were assessed for eligibility between Aug 13, 2015, and June 10, 2016.

78 -morbidities that could influence transplant eligibility by race/ethnicity.

79 omorbidities that could influence transplant eligibility by race/ethnicity.

80 sensitivity to a NAT2 LOH therapy and their eligibility can be assessed by clinical sequencing.

81 On eligibility confirmation, investigators at each site tel

82 tients who received an infusion and for whom eligibility could be confirmed.

83 se they did not receive an infusion or their eligibility could not be confirmed.

84 n reasons for screening out were not meeting eligibility criteria (30-35%) and opting out (23%), and

85 n reasons for screening out were not meeting eligibility criteria (30-35%) and opting-out (23%), and

86 Among 186,046 patients, 64,422 met eligibility criteria (54.3% female; mean age, 61.6 +/- 7

87 eligible) and those meeting a set of limited eligibility criteria (actionable cohort).

88 ed sampling approaches (n = 15), participant eligibility criteria (n = 6), and model-building procedu

89 he proportion of patients meeting PIONEER-HF eligibility criteria (PIONEER-HF eligible) and those mee

90 Twenty-nine patients who met the eligibility criteria (responders, n = 14, and nonrespond

91 Two patients did not meet the full eligibility criteria after baseline assessment; therefor

92 nt in a postcommercial setting, with relaxed eligibility criteria and bridging therapy, is unknown.

93 riptive reports or observational studies met eligibility criteria and formed the evidentiary basis fo

94 Fifty-eight articles met eligibility criteria and formed the evidentiary basis fo

95 er of clinical trials, including participant eligibility criteria and post-treatment follow-up times

96 robust outcomes data, lack of standard donor eligibility criteria and preservation methods, and logis

97 Participants who met all eligibility criteria and showed at least an initial part

98 llenge worldwide, particularly given complex eligibility criteria and varying time windows for treatm

99 propriate studies, 35 (88%) of which met the eligibility criteria and were included in the final anal

100 tal, 28 studies (n = 3,976 participants) met eligibility criteria and were included in the meta-analy

101 Twenty studies met eligibility criteria and were included in the present me

102 rmed, only 25 of these fit the predetermined eligibility criteria and were thus included in this retr

103 nse was assessed in all patients who met the eligibility criteria and who received at least 8 weeks o

104 treat approach, whereby all patients meeting eligibility criteria are included.

105 rgical care at civilian hospitals if certain eligibility criteria are met.

106 Patients meeting all eligibility criteria at the final screening visit were s

107 secondary care mental health services, with eligibility criteria based on diagnosis and severity of

108 From a total of 672, 33 studies met the eligibility criteria based primarily on the relevance to

109 in this SOC study would not have met ZUMA-1 eligibility criteria because of comorbidities at the tim

110 However, the eligibility criteria contained within may inadvertently

111 Some eligibility criteria differed between these studies.

112 tral nervous system or leptomeninges who met eligibility criteria for (131)I-omburtamab therapy under

113 ol and Prevention's recommendations, Medical Eligibility Criteria for Contraceptive Use, provided the

114 ith fixed effects, which made use of the age-eligibility criteria for free bus passes and addressed b

115 Eligibility criteria for inclusion into the review were

116 Fifteen ontologies met the eligibility criteria for inclusion, developed in areas s

117 49 identified abstracts, four trials met our eligibility criteria for inclusion: WAKE-UP, EXTEND, THA

118 tion, which were predominantly AIDS-defining eligibility criteria for initiating ART.

119 nters for Medicare & Medicaid Services (CMS) eligibility criteria for lung cancer screening with CT r

120 aryl-coenzyme A reductase inhibitor (statin) eligibility criteria for primary prevention to include m

121 ncreased risk of lung cancer but do not meet eligibility criteria for screening, as well as multiple

122 view included 16 studies, 9 of which met the eligibility criteria for the meta-analysis.

123 We estimated costs by applying the eligibility criteria for the shorter regimen, and propor

124 creas and kidney (SPK) transplant and define eligibility criteria for those with type 2 diabetes mell

125 outline current knowledge on disparities in eligibility criteria for, access to, and implementation

126 Eligibility criteria in PARADIGM-HF included New York He

127 Eligibility criteria included age 18 years or older and

128 Eligibility criteria included age at least 18 years, cen

129 Eligibility criteria included histologically confirmed H

130 Eligibility criteria included inadequate response to or

131 Eligibility criteria included measurable disease, 1-3 pr

132 Eligibility criteria included patients with p16-positive

133 Eligibility criteria included presence of measurable dis

134 Of these, 1750 (65%) met all of the eligibility criteria on telephone screening and underwen

135 This statement identifies the impact of LCS eligibility criteria on vulnerable populations who are a

136 This analysis included all patients who met eligibility criteria on whom we had complete data on cov

137 group, on further scrutiny, did not meet all eligibility criteria or withdrew from the study.

138 Patients who enrolled in SHORE fulfilled eligibility criteria per protocol (N = 202).

139 We applied pre-specified eligibility criteria to all retrieved records and integr

140 Key eligibility criteria were a total Thacher rickets severi

141 Key eligibility criteria were aged 12 years or older, Easter

142 The eligibility criteria were as follows: comparative studie

143 All available cases meeting eligibility criteria were enrolled.

144 Four patients who did not meet the eligibility criteria were excluded.

145 A total of 1,352 CA patients fulfilled the eligibility criteria were included.

146 Eligibility criteria were modeled on those for the Early

147 ment (N=3515), 734 patients who met SERAPHIN eligibility criteria were selected and their data used t

148 Eligibility criteria were the presence of any thoracic c

149 Overall, 572 patients met eligibility criteria with 2855 patient-years of follow-u

150 2161 patients met eligibility criteria with 876 (41%) transitioned to oral

151 5/478; 95% CI, 6%-12%) described participant eligibility criteria with settings for data collection,

152 Of 37,050 patients who met the eligibility criteria, 529 patients (1.4%) developed symp

153 140 patients did not meet eligibility criteria, and 535 patients were randomly ass

154 hom 1389 (89%) were screened, 1021 (74%) met eligibility criteria, and 975 (95%) were enrolled and fo

155 After screening, applying eligibility criteria, and quality appraisal, 37 articles

156 Determining eligibility criteria, as well as peritransplant and post

157 e specific team structures, modified patient eligibility criteria, cannulation strategies, and manage

158 ethods, setting, population characteristics, eligibility criteria, interventions, numbers enrolled an

159 Our trial had broad eligibility criteria, leading to a large, heterogeneous

160 ons include incomplete data on potential ART eligibility criteria, such as clinical status, pregnancy

161 Of the 1,595 PLHIV who met eligibility criteria, the majority (61%) were inpatients

162 xt studies assessed for eligibility, 116 met eligibility criteria, which included studies describing

163 nd, and the United States/Latin America, met eligibility criteria.

164 T between January 2017 and July 2019 met the eligibility criteria.

165 care and were often uncertain about hospice eligibility criteria.

166 at 3T between January 2017 and July 2019 met eligibility criteria.

167 pplied in nine databases and 12 articles met eligibility criteria.

168 cer at the NIRS, 1455 (92%) patients met the eligibility criteria.

169 The trial included 1151 patients who met eligibility criteria.

170 ze of 162 because too few volunteers met the eligibility criteria.

171 cerns around using aspirin and meeting trial eligibility criteria.

172 vous system (CNS) involvement, due to strict eligibility criteria.

173 There was heterogeneity in other eligibility criteria.

174 A total of 3912 patients met study eligibility criteria.

175 y to a minority of patients due to stringent eligibility criteria.

176 quentially into each eye of patients meeting eligibility criteria.

177 36 articles, relating to 30 studies, met the eligibility criteria.

178 s in higher-resource settings would meet WHO eligibility criteria.

179 ed, and 87.1% (825 of 946) of responders met eligibility criteria.

180 through 60 years were enrolled after meeting eligibility criteria.

181 We included 18 studies that met our strict eligibility criteria.

182 nset using standard intravenous thrombolysis eligibility criteria.

183 ed controlled trials of systemic therapy met eligibility criteria.

184 DESIGN , DATA SOURCES AND ELIGIBILITY CRITERIA: We systematically searched databas

185 d HIV research domain and type of hemoglobin eligibility criterion, but individual associations did n

186 nefits and harms of using ID as a transplant eligibility criterion, review current clinical evidence

187 after ruxolitinib could be considered as an eligibility criterion.

188 Screening for eligibility, data extraction, and quality appraisal were

189 Differences in medical eligibility do not appear to explain racial/ethnic dispa

190 th regulatory and logistical, spanning donor eligibility, donor recruitment, collections, and transfu

191 ivity should be considered for IS withdrawal eligibility; during IS minimization, dnDSA development w

192 sk-based strategy demonstrated low levels of eligibility (few screenings) in the 40-44-year age group

193 eened 2385 death notifications for inclusion eligibility, following which 1295 families were approach

194 c methodological changes, designed to expand eligibility for allo-HSCT to older patients and/or those

195 comfortable if the purpose was to determine eligibility for coverage or reimbursement (v 50.9% at ba

196 Eligibility for disease-specific therapy based on MWT wa

197 nosis of left ventricular hypertrophy (LVH), eligibility for disease-specific therapy, and prognosis.

198 predonation screening is required to assess eligibility for donation to avoid the rejection of suita

199 ians recommends action to enhance and expand eligibility for health insurance financial subsidies; st

200 Two reviewers independently assessed eligibility for inclusion and extracted data from the re

201 a structural anomaly were screened for their eligibility for inclusion in our study.

202 The study also determined potential eligibility for intensive lipid-lowering therapies (very

203 nset, year of birth, vaccination status, and eligibility for MCV doses in the country reporting the c

204 Eligibility for repeat testing (>1,000 copies/mL) was as

205 ation, and readiness assessment-to ascertain eligibility for same-day initiation or refer for further

206 ntiretroviral therapy (ART), but evidence on eligibility for same-day initiation, how best to impleme

207 that allows healthcare workers to determine eligibility for same-day treatment and to initiate ART a

208 4, 2016, we assessed 118 260 women for their eligibility for screening, of whom 111 851 (94.6%) women

209 Eligibility for somatostatin receptor (SSTR) radionuclid

210 R rate, 37%; partial response rate, 48%) and eligibility for surgery in 24 (42%).

211 ive equipment (PPE) usage decisions, dictate eligibility for surgery, or inform administration of imm

212 ) based on aortic diameter, growth rate, and eligibility for surgical intervention.

213 Eligibility for the bus pass was associated with a 7% in

214 quantify the effect of an intervention when eligibility for the intervention is based on a defined c

215 We assessed eligibility for the shorter regimen among US MDR-TB case

216 Eligibility for this study includes poor-risk rel/ref ag

217 the prevalence of comorbidities that affect eligibility for transplant contribute to disparities in

218 the prevalence of co-morbidities that affect eligibility for transplant contribute to disparities in

219 Eligibility for treatment of HER2-positive early breast

220 pared four different strategies to determine eligibility for treatment: using 2011 UK National Instit

221 or to baseline testing plus annual testing, eligibility for universal ART, and patient-centered care

222 rformance from Grade 9 (grade point sum, non-eligibility for upper secondary school and national test

223 Restricted eligibility for welfare support decreased the odds of ge

224 , 2014, to March 31, 2017, when national ART-eligibility guidelines expanded from CD4 counts of less

225 Universal ART eligibility has increased rapid treatment initiation amo

226 a systematic random sample was assessed for eligibility (HIV+, age >= 14 years, on ART >6 months, no

227 with severe side effects that limit patient eligibility, identification of novel therapeutic AML tar

228 e HIV testing and the rapid expansion of ART eligibility in the control group.

229 dy) and 684 infants (110 of 114 assessed for eligibility in the control study and 574 of 684 assessed

230 eading to nearly universal risk-based statin eligibility in the elderly population.

231 he control study and 100 of 129 assessed for eligibility in the novel OPV2 study) and 684 infants (11

232 he control study and 574 of 684 assessed for eligibility in the novel OPV2 study) were enrolled and r

233 ulations, CXR-LC was more sensitive than CMS eligibility in the PLCO data set (74.9% vs. 63.8%; P = 0

234 ograms and mass-vaccination campaigns define eligibility in this way.

235 p ESRD, increased the likelihood of referral eligibility in those who did develop ESRD, and referred

236 Eligibility included 1 cm or larger invasive tumor and g

237 The most common income eligibility limit was 500% of the federal poverty level.

238 aves (1989-1990 and 1992-1993) from Medicare eligibility lists in Forsyth County, North Carolina; Sac

239 Two researchers independently assessed eligibility of retrieved studies and extracted data, inc

240 The eligibility of studies was evaluated independently by th

241 Dec 24, 2015, 122 patients were assessed for eligibility, of which 106 (87%) patients were given acal

242 s, 1081 full-text articles were assessed for eligibility, of which 185 were identified as eligible.

243 1071 records were screened for eligibility, of which 351 were eligible for full-text sc

244 pril 9, 2018, 566 patients were assessed for eligibility, of whom 104 patients were randomly assigned

245 arch 6, 2018, 183 patients were screened for eligibility, of whom 140 (76%) were eligible and were ra

246 rch 17, 2017, 236 patients were screened for eligibility, of whom 181 (77%) were enrolled and randoml

247 July 12, 2019, 429 adults were assessed for eligibility, of whom 251 (59%) were enrolled and randoml

248 d March 1, 2019, we assessed 39 patients for eligibility, of whom 30 patients were enrolled.

249 18, 2014, 3091 individuals were screened for eligibility, of whom 3053 were recruited, and 3022 (1507

250 ological treatment for IBS were assessed for eligibility, of whom 354 were randomly allocated to the

251 Sept 21, 2018, 90 patients were assessed for eligibility, of whom 43 were enrolled and randomly assig

252 30, 2013, we assessed 962 patients for their eligibility, of whom 431 (45%) patients were excluded (1

253 , and Nov 7, 2016, 601 patients assessed for eligibility, of whom 452 patients were enrolled and 226

254 nd Aug 25, 2018, we screened 51 patients for eligibility, of whom 46 patients were enrolled and recei

255 ept 20, 2018, 143 patients were screened for eligibility, of whom 50 patients were enrolled into the

256 Sept 7, 2018, 88 patients were assessed for eligibility, of whom 70 were randomly assigned to treatm

257 participants were recruited and assessed for eligibility, of whom 747 were randomly allocated either

258 uly 7, 2010, 1196 patients were assessed for eligibility, of whom 808 were enrolled and randomly assi

259 wn about the design of the programs, patient eligibility, or drug coverage.

260 nse system, with stratification by cisplatin eligibility, PD-L1 status, and presence or absence of li

261 rve [AUC]) for incident lung cancer than CMS eligibility (PLCO AUC, 0.755 vs. 0.634; P < 0.001).

262 her universal antiretroviral treatment (ART) eligibility policies (Treat All) improved rapid ART init

263 her universal antiretroviral treatment (ART) eligibility policies (Treat All) improved rapid ART init

264 versus "unrestrictive" (deferring to center eligibility policies).

265 Feasibility outcomes included eligibility, recruitment and attrition rates, and fideli

266 Eligibility required measurable disease (according to Re

267 Fifty-five of 72 applicants met eligibility requirements and were invited to take the on

268 of vaginal metronidazole gel as part of the eligibility requirements were randomly assigned, in a 2:

269 lude research, public health statistics, and eligibility rules for privileges or benefits.

270 fects using exogenous variation in programme eligibility rules that limited enrolment in SMSXXI to ch

271 ter utility in a primary care setting and in eligibility screening for clinical trials.

272 ng on the Simplified Algorithm for Treatment Eligibility (SLATE) I trial, in which nearly half of par

273 The Simplified Algorithm for Treatment Eligibility (SLATE) study evaluated a clinical algorithm

274 ion treatment (allocation by transplantation eligibility status); intensification treatment (allocati

275 -based criteria used to determine transplant eligibility, the ID criterion remains controversial beca

276 ts above/below the 200 pmol/L clinical trial eligibility threshold at the 12-month visit.

277 d data entry system that confirmed enrolment eligibility to inhaled 7% hypertonic saline or 0.9% isot

278 Eligibility to participate in the study did not depend o

279 essary in Italy to obtain the certificate of eligibility to practice sports.

280 n) signatures of reinforcement learning with eligibility trace across multiple sensory modalities.

281 n those states for which RL with and without eligibility trace make qualitatively distinct prediction

282 Thus, a widely-distributed feature-specific eligibility trace may be used to update synaptic weights

283 repetitions of the task, whereas models with eligibility traces reinforce entire sequences of actions

284 ement Hebbian forms with neuromodulation and eligibility traces, while true supervised types go even

285 is (AH) is controversial: many centers delay eligibility until a specific period of sobriety (such as

286 6 items covering the following areas: center eligibility, validation of databases, patient cohort sel

287 Statin treatment eligibility was determined by predicted 10-year ASCVD ri

288 Statin therapy eligibility was determined using the 2013 ACC/AHA and 20

289 Eligibility was highest in the East South Central Census

290 Study eligibility was independently evaluated by two researche

291 Eligibility was modified midtrial to exclude subjects wi

292 Eligibility was restricted to human participants and stu

293 lling for covariates, the effect of discount eligibility was significant on dental treatment visits (

294 Dec 31, 2015, of 1794 patients assessed for eligibility, we analysed 1691 patients with candida bloo

295 y 14, 2017, 128 of 351 patients assessed for eligibility were eligible and randomly assigned to recei

296 e 25, 2018, 466 patients of 569 assessed for eligibility were enrolled.

297 , 500 (96%) of the 520 children screened for eligibility were enrolled.

298 oval, titles and abstracts were screened for eligibility with a total of 34 studies included in the f

299 July 1, 2019, 998 patients were screened for eligibility, with 68 being enrolled and randomly assigne

300 e examined the impact that widening LAM test eligibility would have on TB incidence and mortality.